Here's what student-founded startups are leaving CERAWeek with fresh funding. Photo courtesy of HETI

For the third year, the Greater Houston Partnership's Houston Energy Transition Institute hosted its startup pitch competition at CERAWeek by S&P Global. A dozen startups walked away with recognition — and three some with cash prizes.

HETI joined partners Rice Alliance for Technology and Entrepreneurship and TEX-E for the 2024 Energy Venture Day and Pitch Competition at CERAWeek on Wednesday, March 20. Forty-two companies, which have collectively raised over $265 million in investment funding already, pitched to judges. Nine startups won awards across three tracks.

TEX-E, a Texas nonprofit that supports student-founded upstarts, had five of its companies pitch and three winners walked away with monetary prizes. Teams that competed in the TEX-E Prize track, many of which come from Houston universities, include:

  • AirMax, University of Texas at Austin
  • BeadBlocker, University of Houston
  • Carvis Energy Solutions, Texas A&M University
  • Coflux Purification, Rice University
  • Solidec, Rice University

Solidec, which is working on a platform to produce chemicals from captured carbon, won first place and $25,000. The company also recently scored a $100,000 grant from Rice's One Small Step Grant program, as well as a voucher from the DOE. Coflux Purification, which has a technology that destroys PFAS in filtration, won second place and$15,000. The company also secured a One Small Step Grant to the tune of $80,000. AirMax, which focuses on optimizing sustainability for air conditioning equipment, won third place and $10,000.

Last year, Houston-based Helix Earth Technologies took home the top TEX-E price and $25,000 cash awards. The venture, founded by Rawand Rasheed and Brad Husick from Rice University, developed high-speed, high-efficiency filter systems derived from technology originating at NASA.

The rest of the companies that pitched competed for non-monetary awards. Here's what companies won:

  • Group A (CCUS, oilfield solutions, analytics and minerals):
    • First place: Ardent
    • Second place: Vaulted Deep
    • Third place: Mitico
  • Group B (batteries, renewables, water, and grid technology):
    • First place: SungreenH2
    • Second place: FeX Energy
    • Third place: Mercurius Biorefining
  • Group C (Mobility, Materials, and hydrogen solutions)
    • First place: Thiozen
    • Second place: Power2Hydrogen
    • Third place: Arolytics
HETI, Rice Alliance, and TEX-E celebrated the winners at a private reception on Wednesday evening.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”